G1
G1G.F Zelira Therapeutics Limited
- Market cap
- EUR 3.94M
- P/E
- -
- P/B
- 0.32x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2025.
Is G1G.F undervalued?
Graham numberThe Graham number of Zelira Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zelira Therapeutics Limited fundamental analysis
No fundamental analysis for Zelira Therapeutics Limited yet.
Zelira Therapeutics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zelira Therapeutics Limited
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, i…
Full company profileZelira Therapeutics Limited financial statements
Zelira Therapeutics Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 314K | 859K | - | 663K | 1.54M | 301K | 95.0K | 656.00 |
| Gross Profit | 300K | 100K | 314K | 859K | - | 435K | 602K | -61.4K | 10.3K | -8.17K |
| Operating Income | -876K | -6.32M | -2.83M | -4.24M | -7.94M | -9.76M | -13.6M | -7.26M | -5.94M | -3.81M |
| EBITDA | - | - | - | - | -6.73M | -8.03M | -11.8M | -5.65M | -35.5M | -3.17M |
| Net Income | -899K | -6.16M | -1.73M | -3.57M | -7.02M | -8.55M | -11.9M | -5.57M | -36.6M | -3.63M |
| EPS | - | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | -1.25 | -0.49 | -3.22 | -0.30 |
| Balance Sheet | ||||||||||
| Total Assets | 87.5K | 7.97M | 6.31M | 3.52M | 35.8M | 39.4M | 37.7M | 33.9M | 5.18M | 1.30M |
| Total Liabilities | 290K | 70.6K | 99.4K | 407K | 1.24M | 1.54M | 2.01M | 2.18M | 9.36M | 5.59M |
| Shareholders' Equity | -203K | 7.90M | 6.21M | 3.11M | 34.5M | 37.8M | 35.2M | 31.8M | -4.51M | -4.46M |
| Cash & Short-term Investments | 55.7K | 7.87M | 5.69M | 3.07M | 1.70M | 4.97M | 2.75M | 146K | 586K | 5.66K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -334K | -2.20M | -2.62M | -3.34M | -6.94M | -8.62M | -9.43M | -7.25M | - | - |
| Capital Expenditure | 7.09K | 7.09K | 28.2K | 28.2K | 16.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -2.21M | -2.62M | -3.34M | -6.94M | -8.62M | -9.43M | -7.25M | -4.39M | -4.91M |
| Ratios | ||||||||||
| ROE | - | -78.0% | -27.8% | -114.8% | -20.3% | -22.6% | -33.9% | -17.5% | - | - |
| ROA | -1,026.8% | -77.3% | -27.4% | -101.5% | -19.6% | -21.7% | -31.7% | -16.4% | -705.5% | -278.9% |
| Net Profit Margin | - | - | -551.3% | -415.3% | - | -1,288.8% | -775.4% | -1,850.8% | -38,513.0% | -553,029.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Zelira Therapeutics Limited dividends
Zelira Therapeutics Limited has not paid dividends in the last 10 fiscal years.
Last stock split: 1:175 on Apr 14, 2022.
Who owns Zelira Therapeutics Limited
- Insiders 56.70%
- Institutions 0.00%
- Public & others 43.30%
- Shares outstanding 13.1M
- Free float 6.01M
Zelira Therapeutics Limited company profile
- Company name
- Zelira Therapeutics Limited
- Ticker
- G1G.F
- ISIN
- AU000000ZLD1
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 101 St Georges Terrace, Perth, WA, Australia, 6000
- Phone
- 61 8 6558 0886
- Website
- zeliratx.com
About Zelira Therapeutics Limited
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.
Zelira Therapeutics Limited management
6- Mr. Osagie O. Imasogie Esq.Founder & Chairman · born 1962
- Dr. Oludare OdumosuMD, Global CEO & Director
- Mr. Greg BlakeExecutive Director
- Mr. Timothy Ryan SlateCompany Secretary & Non-Executive Director
- Mr. Rahul GanesanVice President of Finance & Accounting
- Dr. Patty WasherClinical Trial Consultant